Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

MENOPAUSAL THERAPY IN FOCUS — The FDA will hold a panel discussion Thursday on hormone therapy for menopausal women, a pet ...

The Food and Drug Administration is reassessing some warnings given about hormone therapy treatments for menopause that have ...

A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on ...

Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

“The role of testosterone is just a lesson in gender bias,” says Kelly Casperson, MD, a urologist. “Because 100 percent of ...

Puerto Rican Gov. Jennifer Gonzalez signed a bill into law that bans hormone therapy and gender-affirming surgeries for ...

Overall, this suggests that the cumulative risk of breast cancer before age 55 for women taking estrogen/progestin is about 4.5%, compared with 4.1% among women who never used hormone therapy and 3.6% ...

Hormone therapy can be used to boost hormone levels and relieve menopause symptoms, which typically last an average of five years but can be as long as 10 years.

An Food and Drug Administration expert panel on Thursday endorsed removing the "black box" warning on hormone treatments for ...